Exchange Traded Concepts’s Ginkgo Bioworks DNA Stock Holding History

Exchange Traded Concepts’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.56M	Buy	358,783 +36,821	+11%	+$308K	0.02%	560
2026 Q1	$1.97M	Sell	321,962 -27,831	-8%	-$231K	0.01%	620
2025 Q4	$2.91M	Buy	349,793 +17,625	+5%	+$190K	0.02%	515
2025 Q3	$4.84M	Buy	332,168 +36,681	+12%	+$439K	0.04%	398
2025 Q2	$3.32M	Sell	295,487 -16,359	-5%	-$127K	0.04%	398
2025 Q1	$1.78M	Buy	311,846 +120,572	+63%	+$1.23M	0.03%	413
2024 Q4	$1.88M	Sell	191,274 -175,704	-48%	-$1.51M	0.04%	395
2024 Q3	$2.99M	Buy	366,978 +209,104	+132%	+$2.1M	0.07%	236
2024 Q2	$2.11M	Buy	157,874 +73,152	+86%	+$2.18M	0.05%	283
2024 Q1	$3.93M	Buy	84,722 +72,027	+567%	+$3.73M	0.1%	193
2023 Q4	$858K	Buy	12,695 +2,748	+28%	+$168K	0.02%	436
2023 Q3	$720K	Buy	9,947 +8,115	+443%	+$649K	0.02%	451
2023 Q2	$136K	Buy	+1,832	New	+$108K	﹤0.01%	872
2022 Q1	–	Sell	-1,618	Closed	-$538K	–	1244
2021 Q4	$538K	Buy	+1,618	New	+$769K	0.01%	655

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Exchange Traded Concepts's DNA Position: Q2 2026 in Review

Exchange Traded Concepts increased its Ginkgo Bioworks (DNA) stake by 11% in Q2 2026, buying an estimated $308K and bringing the position to 358,783 shares worth $3.56M. The position accounts for 0.02% of the portfolio, ranked #560.

Exchange Traded Concepts first reported a position in DNA in Q4 2021 and has held it in 14 quarters since. The position peaked at $4.84M in Q3 2025. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Exchange Traded Concepts held 358,783 shares of Ginkgo Bioworks worth $3.56M as of Q2 2026.
Exchange Traded Concepts bought 36,821 Ginkgo Bioworks shares in Q2 2026, an estimated $308K.
Ginkgo Bioworks made up 0.02% of Exchange Traded Concepts's portfolio in Q2 2026, its #560 holding.
Exchange Traded Concepts first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 14 quarters since.
Exchange Traded Concepts's Ginkgo Bioworks position peaked at $4.84M in Q3 2025.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.